Yüklüyor......
Differentiating mTOR Inhibitors in Renal Cell Carcinoma
PI3K/Akt/mTOR signalling is dysregulated in many cancers, including renal cell carcinoma (RCC), and activation of this pathway has been suggested to correlate with aggressive behavior and poor prognosis in RCC tumors. mTOR inhibition plays a principal role in the targeted treatment of many cancer ty...
Kaydedildi:
| Yayımlandı: | Cancer Treat Rev |
|---|---|
| Asıl Yazarlar: | , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
2013
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4957946/ https://ncbi.nlm.nih.gov/pubmed/23433636 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ctrv.2012.12.015 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|